-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The COVID-19 pandemic has brought unprecedented challenges to the global health care system.
COVID-19 cardiac vascular diabetes diagnosis
Katlyn Nemani and others evaluated whether the diagnosis of schizophrenia spectrum disorder, mood disorder or anxiety disorder in patients with COVID-19 is related to mortality.
JAMA
This retrospective cohort study conducted a 45-day laboratory-confirmed COVID-19 assessment on 7348 consecutive adult patients in the large academic medical system in New York from March 3 to May 31, 2020.
According to the patient’s examination date, according to the tenth revision of the International Statistical Classification of the following diseases, the clinical revised diagnosis classifies patients: (1) schizophrenia spectrum disorder, (2) mood disorder and (3) anxiety disorder .
The main outcome and measure is mortality, which is defined as death or dying within 45 days after the SARS-CoV-2 test result is positive.
A total of 26,540 patients were enrolled, and 7348 were SARS-CoV-2 positive (mean [SD] age: 54 [18.
Odds ratio and ratio of lifelong psychiatric diagnosis to 45-day mortality
Odds ratio and ratio of lifelong psychiatric diagnosis to 45-day mortalityProbability and rate of 45-day mortality of recent psychiatric diagnosis
Probability and rate of 45-day mortality of recent psychiatric diagnosisIn this retrospective cohort study of 7348 confirmed COVID-19 patients, after controlling for age, gender, race, and known medical risk factors, the diagnosis of schizophrenia spectrum was associated with an increase in mortality at 45 days .
Schizophrenia spectrum diagnosis is associated with an increase in mortality at 45 days.
Schizophrenia spectrum disorder may be a risk factor for death of COVID-19 patients.
Targeted interventions may be needed for patients with severe mental illness to prevent worsening health gaps.
Original source
Nemani K, Li C, Olfson M, et al.
Nemani K, Li C, Olfson M, et al.
Association of Psychiatric Disorders With Mortality Among Patients With COVID-19.
JAMA Psychiatry .
2021;78(4):380–386.
doi:10.
1001/jamapsychiatry.
2020.
4442 Nemani K, Li C, Olfson M, et al.
Association of Psychiatric Disorders With Mortality Among Patients With COVID-19.
JAMA Psychiatry .
2021;78(4):380–386.
doi:10.
1001/jamapsychiatry.
2020.
4442 JAMA Psychiatry .
Leave a message here